PTC Therapeutics executive Pierre Gravier reported an automatic sale of PTC Therapeutics, Inc. common stock on July 14, 2026, tied to the vesting of restricted stock units rather than a discretionary market sale. The Form 4 reports that Gravier sold 3,494 shares of PTCT common stock at $80.35 per share, a transaction valued at approximately $280,742.90. The sale was reported as a sell transaction, commonly reflected under transaction code “S” on Form 4 filings. According to the explanatory note, the shares were “automatically sold pursuant to an irrevocable sell to cover election” that Gravier entered into when accepting the equity grant. The purpose was to satisfy tax withholding obligations triggered by the vesting of restricted stock units. The tax-related sale was connected to the vesting of 6,500 RSUs from a July 13, 2023 grant covering 26,000 RSUs. After the 3,494 shares were sold to cover withholding taxes, the vesting would have left Gravier with a net 3,006 shares from that tranche, before considering any other holdings or transactions. The filing also notes that Gravier’s reported common stock ownership includes 162 shares acquired through PTC Therapeutics’ employee stock purchase plan for the period ended June 30, 2026. The document excerpt does not provide a clear total number of shares beneficially owned by Gravier after the transaction. The action is notable mainly as a routine equity-compensation event: RSUs vested, shares were issued, and a portion was automatically sold to meet tax obligations. The filing was signed on July 16, 2026 by Avraham S. Adler as attorney-in-fact for the reporting person.